PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. In Vivo PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Three-week-old male NMRI mice Dosage: 0.25 mg/kg, 1 mg/kg, 5 mg/kg Administration: IP; daily; starting on the day of infection and continuing for an additional four days Result: Effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice. Form:Solid